Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

While not an official condition, this wave of depressive-like symptoms can be overwhelming. Therapists share the red flags ...

A generative AI–powered therapy chatbot is linked to significant reductions in symptoms of depression, anxiety, and eating ...

Recognizing how persistent depressive disorder manifests and plays out in the lives of individuals is the first step in ...

Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. | Cigna's Evernorth unit ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, ...

Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...

Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime ...